A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naive Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Jul 2019 Planned End Date changed from 31 Dec 2019 to 18 Dec 2019.
- 23 Jul 2019 Planned primary completion date changed from 30 Apr 2019 to 18 Dec 2019.
- 23 Jul 2019 Status changed from not yet recruiting to recruiting.